Nuveen Asset Management, LLC Checkpoint Therapeutics, Inc. Transaction History

Nuveen Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$2.36 - $3.2 $590,422 - $800,572	-250,179 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$2.6 - $4.16 $19,721 - $31,553	7,585 Added 3.13%	250,179 $786,000
Q4 2020 Feb 16, 2021	BUY	$2.19 - $2.96 $62,079 - $83,907	28,347 Added 13.23%	242,594 $643,000
Q3 2020 Nov 16, 2020	BUY	$1.62 - $4.24 $33,151 - $86,767	20,464 Added 10.56%	214,247 $575,000
Q2 2020 Aug 14, 2020	BUY	$1.19 - $2.27 $118,696 - $226,421	99,745 Added 106.07%	193,783 $384,000
Q1 2020 May 14, 2020	BUY	$1.11 - $2.43 $33,906 - $74,226	30,546 Added 48.11%	94,038 $141,000
Q3 2019 Nov 14, 2019	BUY	$2.15 - $3.36 $660 - $1,031	307 Added 0.49%	63,492 $158,000
Q2 2019 Aug 15, 2019	BUY	$2.75 - $5.0 $173,758 - $315,925	63,185 New	63,185 $191,000

1.91M

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $234M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.